Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

Aromatase Inhibitors ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Hormone Sensitive ◽

First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.06.011 ◽

2019 ◽

Vol 19 (6) ◽

pp. e701-e716 ◽

Cited By ~ 1

Author(s):

Angela Toss ◽

Marta Venturelli ◽

Isabella Sperduti ◽

Eleonora Molinaro ◽

Chrystel Isca ◽

...

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Meta Analysis ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.041 ◽

2010 ◽

Vol 10 (4) ◽

pp. 313-317 ◽

Cited By ~ 3

Author(s):

Juan de la Haba-Rodriguez ◽

Rosario González Mancha ◽

Gumersindo Pérez Manga ◽

Enrique Aranda Aguilar ◽

José Manuel Baena Cañada ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

BMC Research Notes ◽

10.1186/1756-0500-5-162 ◽

2012 ◽

Vol 5 (1) ◽

Cited By ~ 2

Author(s):

Lamiaa Boulaamane ◽

Saber Boutayeb ◽

Hassan Errihani

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-013-2082-4 ◽

2013 ◽

Vol 71 (4) ◽

pp. 913-919 ◽

Cited By ~ 16

Author(s):

Hesham Tawfik ◽

Yousri Rostom ◽

Hesham Elghazaly

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdq122 ◽

2010 ◽

Vol 21 (12) ◽

pp. 2305-2315 ◽

Cited By ~ 23

Author(s):

A. Chan ◽

D.W. Miles ◽

X. Pivot

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry

10.1158/1538-7445.sabcs20-ps12-21 ◽

2021 ◽

Author(s):

Gabriel Rinnerthaler ◽

Simon P Gampenrieder ◽

Christoph Tinchon ◽

Andreas Leo Petzer ◽

Christoph Suppan ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Everyday Practice ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Epirubicin-Vinorelbine Intravenous Combination Followed by Oral Vinorelbine as First-Line Treatment in Metastatic Breast Cancer

Tumori Journal ◽

10.1177/030089160709300605 ◽

2007 ◽

Vol 93 (6) ◽

pp. 544-549 ◽

Cited By ~ 3

Author(s):

Antonio Ardizzoia ◽

Ilaria Colombo ◽

Monica Giordano ◽

Stefania Aglione ◽

Luciano Isa ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Oral Vinorelbine ◽

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05070-2 ◽

2018 ◽

Vol 174 (2) ◽

pp. 433-442 ◽

Cited By ~ 17

Author(s):

O. Nanni ◽

◽

D. Amadori ◽

A. De Censi ◽

A. Rocca ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Clinical Trial ◽

Randomized Phase 2 ◽

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

OncoTargets and Therapy ◽

10.2147/ott.s103954 ◽

2016 ◽

Vol Volume 9 ◽

pp. 3771-3781 ◽

Cited By ~ 3

Author(s):

Xiao-Qun Liu ◽

Xiangdong Liu ◽

Tiankui Qiao ◽

Wei Chen ◽

Sujuan Yuan

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Randomized Controlled ◽

Locally Recurrent ◽